Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 12, 2011, Pages 2894-2900

  Kahwaji, Joseph ^a   Sinha, Aditi ^b   Toyoda, Mieko ^a   Ge, Shili ^a   Reinsmoen, Nancy ^a   Cao, Kai ^a   Lai, Chih Hung ^a   Villicana, Rafael ^a   Peng, Alice ^a   Jordan, Stanley ^a   Vo, Ashley ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; RITUXIMAB;

ABSCESS; ADULT; APPENDICITIS; ARTICLE; CELLULITIS; CHOLECYSTITIS; COCCIDIOIDOMYCOSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DESENSITIZATION; DIVERTICULITIS; DRUG INDUCED DISEASE; ESOPHAGITIS; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HERPES ZOSTER; HUMAN; INFECTIOUS COMPLICATION; INFLUENZA A; KIDNEY TRANSPLANTATION; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOSIS; MYOCARDITIS; OUTCOME ASSESSMENT; PERITONITIS; PNEUMONIA; PULMONARY CRYPTOCOCCOSIS; PYELONEPHRITIS; RETROSPECTIVE STUDY; SEPSIS; SURVIVAL; TREATMENT OUTCOME; URINARY TRACT INFECTION; VIREMIA; WOUND INFECTION;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DESENSITIZATION, IMMUNOLOGIC; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFECTION; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 83155192617     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03710411     Document Type: Article

References (26)

1. Kahwaji J, Vo AA, Jordan SC: ABO blood group incompatibility: A diminishing barrier to successful kidney transplantation? Expert Rev Clin Immunol 6: 893-900, 2010
2. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC: Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359: 242-251, 2008
3. Vo A, Peng A, Toyoda M, Kahwaji J, Cao K, Lai C, Reinsmoen N, Villicana R, Jordan S: Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 89: 1095-1102, 2010
4. Sonnenday CJ, Warren DS, Cooper M, Samaniego M, Haas M, King KE, Shirey RS, Simpkins CE, Montgomery RA: Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 4: 1315-1322, 2004
5. Genberg H, Kumlien G, Wennberg L, Berg U, Tydén G: ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: A 3-year follow-up. Transplantation, 85: 1745-1754, 2008
6. Kahwaji J, Tong C, Jordan S, Vo A: Rituximab: An emerging therapeutic agent for kidney transplantation. Transplant Res Risk Management 1: 15-29, 2009
7. Montgomery RA, Locke JE, King KE, Segev DL, Warren DS, Kraus ES, Cooper M, Simpkins CE, Singer AL, Stewart ZA, Melancon JK, Ratner L, Zachary AA, Haas M: ABO incompatible renal transplantation: A paradigm ready for broad implementation. Transplantation 87: 1246-1255, 2009
8. Tanabe K: Japanese experience of ABO-incompatible living kidney transplantation. Transplantation 84: S4-S7, 2007
9. Genberg H, Kumlien G, Wennberg L, Tydén G: Long-term results of ABO-incompatible kidney transplantation with antigen-specific immunoadsorption and rituximab. Transplantation 84: S44-S47, 2007
10. Kelesidis T, Daikos G, Boumpas D, Tsiodras S: Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis, 15: e2-e16, 2011
11. Grim S, Pham T, Thielke J, Sankary H, Oberholzer J, Benedetti E, Clark N: Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients. Clin Transplant 21: 628-632, 2007
12. Basse G, Ribes D, Kamar N, Mehrenberger M, Sallusto F, Esposito L, Guitard J, Lavayssiere L, Oksman F, Durand D, Rostaing L: Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 38: 2308-2310, 2006
13. Faguer S, Kamar N, Guilbeaud-Frugier C, Fort M, Modesto A, Mari A, Ribes D, Cointault O, Lavayssiere L, Guitard J, Durand D, Rostaing L: Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 83: 1277-1280, 2007
14. Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, Barista I: Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 48: 1307-1312, 2007
15. Usui M, Isaji S, Mizuno S, Sakurai H, Uemoto S: Experiences and problems pre-operative anti-CD20 monoclonal antibody infusion therapy with splenectomy and plasma exchange for ABO-incompatible living-donor liver transplantation. Clin Transplant 21: 24-31, 2007
16. Kamar N, Milioto O, Puissant-Lubrano B, Esposito L, Pierre M, Mohamed A, Lavayssière L, Cointault O, Ribes D, Cardeau I, Nogier M, Durand D, Abbal M, Blancher A, Rostaing L: Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 10: 89-98, 2010
17. Zarkhin V, Li L, Kambham N, Sigdel T, Salvatierra O, Sarwal MM: A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 8: 2607-2617, 2008
18. Munoz AS, Rioveros AA, Cabanayan-Casasola CB, Danguilan RA, Ona ET: Rituximab in highly sensitized kidney transplant recipients. Transplant Proc 40: 2218-2221, 2008
19. Vo AA, Wechsler EA, Wang J, Peng A, Toyoda M, Lukovsky M, Reinsmoen N, Jordan SC: Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am J Transplant 8: 144-149, 2008
20. Scemla A, Loupy A, Candon S, Mamzer MF, Martinez F, Zuber J, Sberro R, Legendre C, Thervet E: Incidence of infectious complications in highly sensitized renal transplant recipients treated by rituximab: A case-controlled study. Transplantation 90: 1180-1184, 2010
21. Lai CH, Cao K, Ong G, Naim M, Wang Q, Mirocha J, Vo A, Jordan SC, Reinsmoen NL: Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapy. Transplantation 92: 48-53, 2011
22. Dharnidharka V, Caillard S, Agodoa L, Abbott K: Infection frequency and profile in different age groups of kidney transplant recipients. Transplantation 81: 1662-1667, 2006
23. Leroy F, Sechet A, Abou Ayache R, Thierry A, Belmouaz S, Desport E, Bauwens M, Bridoux F, Touchard G: Cytomegalovirus prophylaxis with intravenous polyvalent immunoglobulin in high-risk renal transplant recipients. Transplant Proc 38: 2324-2326, 2006
24. Wiseman A: Polyomavirus nephropathy: A current perspective and clinical considerations. Am J Kidney Dis 54: 131-142, 2009
25. Randhawa P, Schonder K, Shapiro R, Farasati N, Huang Y: Polyomavirus BK neutralizing activity in human immunoglobulin preparations. Transplantation 89: 1462-1465, 2010
26. Sener A, House AA, Jevnikar AM, Boudville N, McAlister VC, Muirhead N, Rehman F, Luke PP: Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: Oneyear follow-up of renal allograft recipients. Transplantation 81: 117-120, 2006